|
|
|
Sana Biotechnology Inc (NASDAQ: SANA) |
|
Sana Biotechnology Inc
Officers & Directors
Michelle Seitz Director Steven D. Harr, M.D. President, Chief Executive Officer and Director (Principal Executive Officer) Mary Agnes (Maggie) Wilderotter Director Alise S. Reicin, M.D. Director Hans E. Bishop Chairman of the Board Nathan Hardy Chief Financial Officer (Principal Financial and Accounting Officer) Joshua H. Bilenker, M.D. Director Robert Nelsen Director Richard Mulligan, Ph.D. Director Douglas Cole, M.D. Director Patrick Y. Yang, Ph.D. Director ,
Sana Biotechnology Inc currently has 142 employees.
News about Sana Biotechnology Inc Key Personnel |
Sana Biotechnology s Bold Gambit: Fast Tracking into the Future of Autoimmune Treatments Amid Financial TurbulenceBy CSI Market In a move that could reshape the landscape of autoimmune disease treatment, Sana Biotechnology Inc. recently announced it has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for its investigational therapy SC291, aimed at treating relapsed or refractory systemic lupus erythematosus (SLE). This recognition is more than just a badge of honor; it signifies the FDA’s acknowledgment of SC291’s potential to address urgent medical needs in patients battling this complex autoimmune disorder.For Sana, the Fast Track designation comes at a critical...
|
In a recent publication in Nature Biotechnology, Sana Biotechnology has unveiled promising preclinical data showcasing the potential of pluripotent stem cell-derived human glial progenitor cell transplantation as a treatment for Huntington s disease and other glial-based neurodegenerative conditions. The study involved healthy human glial cells being successfully transplanted and replacing diseased glial cells in the brains of human glial chimeric Huntingtin mice. This breakthrough provides hope for new therapeutic approaches in the field of neuroscience.
Impacts on Sana Biotechnology:
While Sana Biotechnology s research achievements are significant, the company recorded a net loss of $280 ...
|
Sana Biotechnology Sets New Course with Upsized Public Offering
In a bold move that demonstrates its commitment to revolutionizing patient care, Sana Biotechnology, Inc. recently revealed the pricing details for its upsized public offering. The company aims to raise approximately $165.0 million in gross proceeds through the sale of 17,272,728 shares of common stock, priced at $5.50 per share, and pre-funded warrants to purchase 12,727,272 shares of common stock, priced at $5.4999 per pre-funded warrant.
In a show of confidence in Sana Biotechnology s potential, the underwriters were granted a 30-day option to purchase up to an additional 4,500,000 shares of common stock. This move highlights the...
|
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.
